Chardan Capital Reiterates Buy on EyePoint Pharmaceuticals, Maintains $21 Price Target
Chardan Capital analyst Daniil Gataulin reiterates EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $21 price target.
Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell
• argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
EyePoint Pharmaceuticals, Rallybio Enter Research Collaboration; Financial Terms Not Disclosed
The partnership will evaluate sustained delivery of Rallybio's inhibitor of complement component 5 (C5) using EyePoint's proprietary Durasert technology for sustained intraocular drug delivery. The initial focus
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Yield10 Bioscience (NASDAQ:YTEN) shares increased by 35.2% to $2.84 during Thursday’s regular session. Trading volume for Yield10…
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 107 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 160 companies set new 52-week lows.
EyePoint Pharmaceuticals Q3 EPS $(0.49) Beats $(0.70) Estimate, Sales $10.01M Miss $10.64M Estimate
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.70) by 30 percent. This is a 15.52 percent increase over losses of $(0.58) per share